Posted on September 18, 2019 by Sitemaster
Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, Erleada, mCSPC, mHSPC, US | Leave a comment »
Posted on July 24, 2019 by Sitemaster
The initial data from the ARCHES study of standard ADT + enzalutamide versus standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer were reported earlier this year at the Genitourinary Cancers Symposium in San Francisco. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, apalutamide, darolutamide, deprivation, enzalutamide | 7 Comments »
Posted on May 31, 2019 by Sitemaster
At the end of January, we had reported that the results of the TITAN trial — the Phase III trial of standard ADT + apalutamide (Erlead) or standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer (mHSPC) — were positive, and that they were going to be reported at a meeting later in the year. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, Erleada, hormone-sensitive, metastatic, mHSPC | 12 Comments »
Posted on April 30, 2019 by Sitemaster
According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval of apalutamide (Eleada) in the treatment of men with metastatic, castration-sensitive prostate cancer (mCSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, castration-sensitive, mCSPC, metastatic, trial, TRITON | 3 Comments »
Posted on January 31, 2019 by Sitemaster
According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-sensitive, Erleada, hormone-sensitive, mCSPC, metastatic, mHSPC, outcome, TITAN, trial | Leave a comment »
Posted on January 17, 2019 by Sitemaster
Yesterday, Janssen Pharmaceuticals announced the approval of apalutamide (Erleada) by the European Commission (EC) for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk for development of metastatic disease. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, castration-resistant, Erleada, EU, Europe, nmCRPC, non-metastatic | 2 Comments »
Posted on August 21, 2018 by Sitemaster
With the relatively recent approvals of apalutamide (Erleada) and enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), we are seeing intense discussion within the urologic oncology and medical oncology communities about the appropriate treatment of patients with this category of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic | 3 Comments »
Posted on February 15, 2018 by Sitemaster
Yesterday afternoon the US Food & Drug Administration (FDA) approved apalutamide — which will have the brand name Erleada — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, Erleada, SPARTAN | Leave a comment »
Posted on February 9, 2018 by Sitemaster
So at the Genitourinary Cancers Symposium in San Francisco today we were presented with full reports on the SPARTAN trial and the PROSPER trial by Drs. Eric Small and Maha Hussain, respectively. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic | 6 Comments »
Posted on February 6, 2018 by Sitemaster
So we now have news reports and abstracts telling us what the top-line results of the SPARTAN trial and the PROSPER trial are in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic, PROSPER, SPARTAN | 17 Comments »
Posted on December 22, 2017 by Sitemaster
Apparently the US Food and Drug Administration (FDA) will give a priority review to apalutamide (formerly known as ARN-509), based on data from the Phase III SPARTAN trial in men with non-metastatic castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metaststic, SPARTAN | 3 Comments »
Posted on May 18, 2017 by Sitemaster
An announcement from Johnson & Johnson yesterday said that the company is projecting filings with regulatory authorities for approval of two new drugs for the treatment of advanced prostate cancer between 2017 and 2021. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: apalutamide, ARN-509, niraparib | 2 Comments »
Posted on May 16, 2016 by Sitemaster
A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: apalutamide, ARN-509, outcomes, trials | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 